Co-founder and CTO


Dr. Martin Akerman is the Co-founder and CTO of Envisagenics. He is the inventor of the SpliceCore software platform, born out of his extensive research experience at the intersection of biology and data science and his vision of discovering RNA therapeutics using machine learning.

Martin trained as a post doctorate fellow with Dr. Adrian Krainer from Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. He received his PhD in Bioinformatics from Technion, Israel Institute of Technology in 2009. As a first-time entrepreneur, Martin represented Envisagenics in winning the J&J AI for Drug Discovery QuickFire challenge in 2017 and Microsoft’s Innovate.AI challenge in 2018.

His goal is to combine cutting-edge computation with RNA domain expertise to develop innovative drugs for cancer and neurodegeneration.

Latest insights

Fri Mar 13 2020

Did an experimental drug help a U.S. coronavirus patient?

Fri Jan 10 2020

MoneyBall Medicine: Tom Davenport on the Analytics Gap in Healthcare

Wed Dec 18 2019

MoneyBall Medicine – Milind Kamkolkar on Seeing the Forest and the Tr...

Fri Nov 8 2019

Gini Deshpande of NuMedii on Augmented Intelligence for Drug Discovery

Never miss an announcement